Normative Database of Healthy Subject Vascular Density Using Spectralis Heidelberg® Optical Coherence Tomography Angiography

NCT ID: NCT06043622

Last Updated: 2024-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-12

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Optical coherence tomography angiography (OCT-A) is a determinant progress to study retinal and choroidal vasculature without using a dye injection. OCT-A yields interesting results in different pathologies such as diabetes mellitus, age-related macular degeneration, hypertension blood pressure, particularly by affecting vascular density. Normative database are necessary to compare OCT-A parameters between patients and controls. However, OCT-A devices from different manufactures may give different values for the same subject. It seems to be obvious that each OCT-A device should have its own normative database. In the literature, OCT-A normative databases are developing using different types of devices, but none is available for Heidelberg OCT-A in Caucasians. The purpose of this project is to create a normative database of retinal microvascularisation using Spectralis Heidelberg optical coherence tomography angiography (OCT-A) ® in normal controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Optical Coherence Tomography Optical Coherence Tomography Angiography

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy subject vascular density

Group Type EXPERIMENTAL

Optical coherence tomography angiography

Intervention Type OTHER

Optical coherence tomography angiography

ophthalmological exam

Intervention Type OTHER

ophthalmological exam

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optical coherence tomography angiography

Optical coherence tomography angiography

Intervention Type OTHER

ophthalmological exam

ophthalmological exam

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Voluntary adult subjects or legal representative consenting for minor or subjects under protection
* Intra ocular pression ≤ 21mmHg
* Spherical refraction comprised between - 6 D and +6 D and/or axial length between 21 and 26mm
* Patient affiliated to social security system

Exclusion Criteria

* Ocular diseases: glaucoma, retinal diseases as diabetic retinopathy, age-related macular degeneration, amblyopia, optic neuropathy
* Diabetes mellitus
* Uncontrolled hypertension blood pressure (\> 140/90)
* Recent ocular surgery (\< 6 months)
* Any ophthalmological conditions interfering with a good ocular examination or OCT quality (cataract, corneal opacity …)
* OCT-A sufficient quality ≥ 25 (0 = bad quality /40 = excellent quality
* Not consenting patient
* Pathological situation or handicap avoiding good installation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GHPSO de Creil

UNKNOWN

Sponsor Role collaborator

Hôpital Saint Vincent de Paul, Lille

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire, Amiens

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Amiens University Hospital

Amiens, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ha-Chau TRAN, Pr

Role: CONTACT

03 22 08 92 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ha-Chau TRAN, Pr

Role: primary

03 22 08 92 00

Sadia ALEM, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI2023_843_0089

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.